Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry

Annals of the Rheumatic Diseases

Volumn 69, Issue 2, 2010, Pages 400-408

  Mariette, Xavier ^a   Tubach, F ^b   Bagheri, H ^c   Bardet, M ^d   Berthelot, J M ^e   Gaudin, P ^f   Heresbach, D ^g   Martin, A ^h   Schaeverbeke, T ⁱ   Salmon, D ^j   Lemann, M ^k   Hermine, O ^l   Raphael, M ^a   Ravaud, P ^b  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^e HÔTEL DIEU   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^h Hôpital de Saint Brieuc   (France)

ⁱ HÔPITAL PELLEGRIN   (France)

^j NONE   (France)

^k SAINT LOUIS HOSPITAL   (France)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; B CELL LYMPHOMA; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; EPSTEIN BARR VIRUS; FEMALE; FRANCE; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; SJOEGREN SYNDROME; T CELL LYMPHOMA;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS; EPIDEMIOLOGIC METHODS; FEMALE; FRANCE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; MALE; MIDDLE AGED; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75849118366     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.117762     Document Type: Article

References (23)

1. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44.
2. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006;98:51-60.
3. Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006;98:1321-30.
4. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
5. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
6. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21.
7. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-9.
8. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-15.
9. Askling J, Baecklund E, Granath F, et al. Anti-TNF therapy in RA and risk of malignant lymphomas. Relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68:648-53.
10. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757-64.
11. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51.
12. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis higher with monoclonal-antibody than with soluble-receptor anti-TNF therapy in the 3-year prospective French RATIO registry. Arthritis Rheum 2009;60:1884-94.
13. Tubach F, Salmon-Ceron D, Ravaud P, et al. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy. Joint Bone Spine 2005;72:456-60.
14. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296.
15. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
16. Bongartz T, Warren F, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. Ann Rheum Dis 2009;68:1177-83.
17. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
18. Direct healthcare professional communication on reports of hepatosplenic T-cell lymphoma in patients treated with Humira (adalimumab). Dear Doctor letter Abbott 16 July 2008.
19. Askling J, Klareskog L, Blomqvist P, et al. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006;65:1184-7.
20. Park SH, Kim CG, Kim JY, et al. Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. Rheumatol Int 2008;28:475-7.
21. Thonhofer R, Gaugg M, Kriessmayr M, et al. Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis 2005;64:1098-9.
22. Baran-Marszak F, Laguillier C, Youlyouz I, et al. Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein-Barr virus. Cytokine 2006;33:337-45.
23. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Therapeut 2002;301:418-26.